Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
A 769662 (HB1351)
Description:Potent, reversible AMPK activator. Inhibits MSC proliferation.
Purity:>98%
AICAR (HB2152)
Description:AMPK activator. Promotes osteogenic differentiation of bone marrow-derived MSCs.
Purity:>99%
Dorsomorphin dihydrochloride (HB2800)
Description:Potent, selective AMPK inhibitor. Promotes neural hPSCs differentiation and promotes cardiomyocyte differentiation in mESCs.
Purity:>98%